Moxeza

Plague, Sinusitis, prophylaxis of Plague + 7 more

Treatment

9 FDA approvals

7 Active Studies for Moxeza

What is Moxeza

Moxifloxacin

The Generic name of this drug

Treatment Summary

Moxifloxacin is an antibiotic drug developed by Bayer AG. It is used to treat bacterial infections and is sold under the brand name Avelox or Avalox. It is a type of fluoroquinolone antibiotic.

Avelox

is the brand name

image of different drug pills on a surface

Moxeza Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Avelox

Moxifloxacin

1999

86

Approved as Treatment by the FDA

Moxifloxacin, also known as Avelox, is approved by the FDA for 9 uses including Sinusitis and Sinusitis .

Sinusitis

Sinusitis

Skin Infections

Plague

Community Acquired Pneumonia (CAP)

Plague

prophylaxis of Plague

Bronchitis

Communicable Diseases

Effectiveness

How Moxeza Affects Patients

Moxifloxacin is an antibiotic that can treat infections caused by certain bacteria. It works by blocking the enzyme that helps the bacteria replicate and spread, and is effective against both Gram-positive and Gram-negative bacteria. Some of the bacteria it can treat include Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, Streptococcus

How Moxeza works in the body

Moxifloxacin works by interfering with two essential bacterial enzymes, DNA gyrase and topoisomerase IV, which are responsible for replicating and repairing bacterial DNA. It also helps to prevent the bacterial DNA from being divided into new cells.

When to interrupt dosage

The proposed measure of Moxeza is contingent upon the determined condition, including ocular bacterial infections, Sinusitis and Skin Infections. The dosage amount fluctuates according to the method of delivery (e.g. Solution - Intravenous or Injection, solution - Ophthalmic) featured in the table beneath.

Condition

Dosage

Administration

Community Acquired Pneumonia (CAP)

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Postoperative Infections

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

prophylaxis of Plague

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Conjunctivitis, Bacterial

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

ocular bacterial infections

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Bronchitis

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Postoperative Inflammatory Response

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Communicable Diseases

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Plague

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Sinusitis

400.0 mg, , 5.0 mg/mL, 0.5 %, 4.0 mg/mL, 1.0 mg/mL, 0.5 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Ophthalmic, Solution - Ophthalmic, Tablet, Tablet - Oral, Solution - Intravenous, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution / drops, Solution / drops - Ophthalmic, Injection, suspension - Ophthalmic, Injection, solution - Ophthalmic, Injection, suspension, Suspension - Ophthalmic, Suspension, Intraocular, Injection, solution - Intraocular, Kit, Kit - Ophthalmic

Warnings

There are 20 known major drug interactions with Moxeza.

Common Moxeza Drug Interactions

Drug Name

Risk Level

Description

Amiodarone

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.

Amitriptyline

Major

Moxifloxacin may increase the QTc-prolonging activities of Amitriptyline.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.

Moxeza Toxicity & Overdose Risk

Signs of an overdose on zopiclone may include reduced alertness, sleepiness, shaking, seizures, vomiting, and diarrhea. The minimum amount required to be fatal in mice and rats is 100mg/kg.

Moxeza Novel Uses: Which Conditions Have a Clinical Trial Featuring Moxeza?

24 active trials are currently in progress to investigate the potential of Moxeza to serve as a prophylaxis for Plague, Skin Infections and Bacterial Conjunctivitis.

Condition

Clinical Trials

Trial Phases

Postoperative Inflammatory Response

0 Actively Recruiting

Plague

0 Actively Recruiting

Postoperative Infections

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

ocular bacterial infections

0 Actively Recruiting

Sinusitis

2 Actively Recruiting

Not Applicable

prophylaxis of Plague

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Moxeza Reviews: What are patients saying about Moxeza?

5

Patient Review

10/7/2013

Moxeza for Pink Eye from Bacterial Infection

I was prescribed this for my 18-month old daughter, but it didn't work out too well. The medication is very thick and difficult to apply to a squirming child's eyes. After seven days of struggle (and no doubt missing some key areas), the infection came back.

5

Patient Review

3/13/2014

Moxeza for Pink Eye from Bacterial Infection

Though they're a bit pricey and hard to use, these drops are worth it according to my doctor. They work much faster than many of the cheaper alternatives.

3.7

Patient Review

1/4/2016

Moxeza for Pink Eye from Bacterial Infection

It took a little longer than I would have liked to see results, but this did eventually treat my pink eye. The six day mark was when things finally cleared up. Another downside is that the drops are very difficult to administer.

3.7

Patient Review

3/27/2015

Moxeza for Pink Eye from Bacterial Infection

I had pink eye for a week and was in so much pain from the burning and swelling. After using these drops, my eyes felt better within hours. My husband helped me put them in, and I was so grateful for the relief that I didn't mind the price or difficulty of administration.

3.3

Patient Review

5/10/2014

Moxeza for Pink Eye from Bacterial Infection

The bottle is very difficult to squeeze drops out of, and the price is too high for treating a minor eye infection

2.3

Patient Review

4/17/2019

Moxeza for Pink Eye from Bacterial Infection

I contacted the manufacturer, Novartis, to ask how to get the drops out of the bottle. They told me that you have to push in on the bottom with your finger so that the drop comes out. I hadn't been able to do it before because I was squeezing the bottle (which you're not supposed to do). The manufacturer needs to put this information on the directions!

2

Patient Review

11/28/2013

Moxeza for Pink Eye from Bacterial Infection

The burning and watering of my eyes was really bad at first, but after a few minutes it began to provide relief from pain and itchiness. By the second day, I felt much better.

2

Patient Review

1/6/2015

Moxeza for Ulcer of the Cornea of the Eye with Bacterial Infection

The administration was difficult due to the small size of the hole. Despite this, I can see why it's such an affordable option. After one day, my eye felt better.

1.7

Patient Review

5/31/2014

Moxeza for Pink Eye from Bacterial Infection

The texture of this cream is really off-putting. I'm not convinced it's effective, either.

1.7

Patient Review

8/24/2013

Moxeza for Pink Eye from Bacterial Infection

1.3

Patient Review

1/5/2014

Moxeza for Pink Eye from Bacterial Infection

I was very disappointed with this medication. It is more expensive than other pink eye treatments, and the thick liquid made it hard to apply.

1.3

Patient Review

9/29/2016

Moxeza for Pink Eye from Bacterial Infection

I am on day 4 of taking these drops and have seen almost no improvement. I'm going to see an eye doctor today to get a different prescription that might actually work. These drops cost me $150 and were completely ineffective.

1.3

Patient Review

7/24/2014

Moxeza for Pink Eye from Bacterial Infection

Get a different antibiotic. There are plenty out there that work just as well. These drops are horrible. I've been using them for pink eye and they are incredibly hard to self administer. I have had several eye infections, burnt cornea etc and I know there are better drops available.

1.3

Patient Review

5/14/2014

Moxeza for Pink Eye from Bacterial Infection

Though this medication is effective for pinkeye, with noticeable improvement within twelve hours, it is unduly difficult to administer. This is especially so considering the high cost of the drug; $125 for three mL. I would recommend a different antibiotic.

1

Patient Review

4/17/2019

Moxeza for Pink Eye from Bacterial Infection

I followed the instructions given by Novartis, but found it difficult to get the product out. Once I finally did, the drop wouldn't release because it was so viscous. It's possible that this is a good product, but I was annoyed by how hard it was to use.

1

Patient Review

11/30/2016

Moxeza for Pink Eye from Bacterial Infection

These drops are ridiculously thick and difficult to administer. They also don't seem to actually go into the eye at all. We saw no results after using this treatment twice and then had to switch to a different, thinner medication which worked perfectly.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about moxeza

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who makes Moxeza?

"Lupin has introduced a new generic treatment option for bacterial conjunctivitis in the form of a 0.5% moxifloxacin ophthalmic solution. This comes after receiving the Food and Drug Administration's approval earlier."

Answered by AI

Does Moxeza have generic?

"- On this day, Lupin launched a generic version of Alcon's Moxeza solution, rated AT. The solution is approved for treating bacterial conjunctivitis caused by susceptible strains of organisms."

Answered by AI

What is Moxeza used for?

"Moxeza is a eye drop used to treat bacterial conjunctivitis or other bacterial infections of the eyes."

Answered by AI

What is the difference between Vigamox and Moxeza?

"The side effects of Vigamox include blurred vision and different eye reactions than those of Moxeza, such as pain, dryness, redness, itching, burning, and stinging. Moxeza may also cause inflammation of the eye, while Vigamox may interact with other eye medications."

Answered by AI

Clinical Trials for Moxeza

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered Moxeza clinical trials?

We made a collection of clinical trials featuring Moxeza, we think they might fit your search criteria.
Go to Trials
Image of Vancouver General Hospital in Vancouver, Canada.

In-Clinic Endoscopic Polypectomy for Nasal Polyps

18+
All Sexes
Vancouver, Canada

Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and headache, an inability to breath through the nose and complete smell loss, regularly impair one's ability to work and to enjoy and participate in daily activities. The annual cost of chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps, the most common type of chronic sinusitis, is usually treated with a combination of medications and surgery. Until now, surgical treatment has only been performed in the operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a new procedure, "in-clinic polyp removal", can provide an improvement in patient symptoms to levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in clinic polyp removal has additional advantages including a shorter procedure recovery time, a significantly lower cost to the health care system (about one-tenth the cost or $450), and a shorter wait time for treatment. With the proposed pragmatic trial, the investigators will determine whether the in clinic polyp removal procedure is as good as sinus surgery in the operating room at controlling patient symptoms of chronic sinusitis. The investigators will also determine the cost and health-benefits for a patient, the healthcare system and for society of in clinic polyp removal in comparison to sinus surgery done in a hospital operating room. The investigators will then know if this new treatment, in clinic polyp removal, can replace sinus surgery as the standard of care for these patients.

Recruiting
Has No Placebo

Vancouver General Hospital (+4 Sites)

Shaun Kilty, MD

Medtronic